StockIQpro
NASDAQ:HOWL

Werewolf Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Werewolf Therapeutics, Inc. reported net income of −$60.8M in fiscal 2025. Free cash flow was −$60.3M, and the diluted share count rose 6.7%.Summary generated from Werewolf Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 27, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−123.9%
Debt / equity1.29
Free cash flow−$60.3M
FCF marginn/a
Share count change+6.7%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−50−56−41−74−61
Net income−50−54−37−71−61
Free cash flow−43−44−33−56−60

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations